Balance of nature.

No, it’s not a health food supplement. Avasopasem manganese, the superoxide dismutase mimetic hitherto known as GC4419, officially had no negative impact on disease control or survival outcomes at 2 years per long-term reporting on the phase 2 trial that brought it fame by demonstrating its ability to significantly reduce the incidence of radiation mucositis and, most notably, slash its duration. This comes on the heels of abstract reporting at this year’s ASCO annual meeting of the follow-on phase 3 double-blind placebo-controlled ROMAN trial (n=407) which further confirmed its efficacy in reducing incidence and duration of radiation mucositis. | Anderson, Int J Radiat Oncol Biol Phys 2022